Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
about
Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathwayNuclear Factor Erythroid 2-related Factor 2 Deficiency Exacerbates Lupus Nephritis in B6/lpr mice by Regulating Th17 Cell FunctionElevated Spontaneous Interferon-γ Secretion in Human Immunodeficiency Virus-Infected PersonsGranulocyte colony-stimulating factor treatment ameliorates lupus nephritis through the expansion of regulatory T cells.Correlation of Serum Soluble Interleukin-7 Receptor and Anti-C1q Antibody in Patients with Systemic Lupus Erythematosus.Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE.IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role.All- Trans-Retinoic Acid Augments the Histopathological Outcome of Neuroinflammation and Neurodegeneration in Lupus-Prone MRL/lpr Mice.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care.The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients.Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus.Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment.Dysregulation of Innate Lymphoid Cells in Common Variable Immunodeficiency.Screening epitopes on systemic lupus erythematosus autoantigens with a peptide array.Defective Suppressor of Cytokine Signaling 1 Signaling Contributes to the Pathogenesis of Systemic Lupus Erythematosus.Immunosuppressive Effect of B7-H4 Pathway in a Murine Systemic Lupus Erythematosus Model.Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous.Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.Pathways of impending disease flare in African-American systemic lupus erythematosus patients.RORγt expression in Tregs promotes systemic lupus erythematosus via IL-17 secretion, alteration of Treg phenotype and suppression of Th2 responses.Detection of epitopes in systemic lupus erythematosus using peptide microarray.Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review.Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.Myeloid-Derived Suppressor Cells Induce Podocyte Injury Through Increasing Reactive Oxygen Species in Lupus Nephritis.
P2860
Q26746697-2906DE33-79DE-4E08-AD3D-30E4B2F093C6Q28396263-68D7317E-81C4-400F-93E1-8A3B23A4CEBBQ33772397-AEF12F48-B2EA-4134-815D-4891B57EC370Q36193272-7CA04A4B-F32F-4699-B827-386400AFF96DQ36741210-D7C2628A-53A1-461C-B5E8-84D76EE19219Q37419371-B0C6CB84-FA0E-4431-8C3F-2C679FCFDCF4Q37679294-D274D6F8-9F38-4C3F-9E19-BF7B8BBD47D3Q38406678-77F43C9F-D5B4-4590-9C48-5BC31E29B616Q38840646-3A71FE50-0754-4E54-B98A-BA96E46481E8Q38851096-31F414FB-BB92-4370-9CBC-D06BBC0F1FB6Q39021621-391E1B45-4C11-495E-8C15-139EDD21D1BEQ39160729-8BC8DD3F-C7FA-4B39-A808-31EB256EC9E1Q40260152-EA9DD662-E101-4572-B13B-C33FE790F23DQ40401297-E5C741C5-1694-4ED0-A16B-533975BC5184Q41146632-0854DB8C-A02E-4D5F-BBA1-1BDBD8DD7554Q41990559-1EDDD1CA-1DF2-475B-827F-68FA328C6098Q45376906-EC569732-139F-4406-A7C0-6C2470130480Q47151871-890193B7-65F7-473B-A44B-97E14F98559AQ47389712-67613BDF-6521-4B59-93C1-7CEA93D05662Q48045890-3D12AA0E-6966-4786-B368-45807191DE70Q49480873-42A5864F-1558-4D1F-9A72-68EDDF90F7A7Q50910971-ECDB20AC-35C5-4103-87C3-D09D97CB881EQ51048914-D0631B9F-C61D-4CD3-A273-81AF0A4BD992Q51147794-F77BCDFA-ECFF-4AEC-BA07-56F13E793BD7Q52584318-75FC1294-7C08-430C-8F5B-DF50649D24DAQ55163735-10790471-3532-49CC-90E8-F81F4DCAC428Q55516372-7665A0F6-8B07-4309-93D0-48856E95F80F
P2860
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@ast
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@en
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@nl
type
label
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@ast
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@en
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@nl
prefLabel
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@ast
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@en
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@nl
P2860
P3181
P356
P1476
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
@en
P2093
Evelyn Tsantikos
Margaret L Hibbs
P2860
P3181
P356
10.3389/FIMMU.2015.00550
P407
P577
2015-10-28T00:00:00Z